Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

136P - Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158

Date

21 Oct 2023

Session

Poster session 01

Topics

Clinical Research;  Genetic and Genomic Testing;  Immunotherapy

Tumour Site

Presenters

Yimin Mao

Citation

Annals of Oncology (2023) 34 (suppl_2): S233-S277. 10.1016/S0923-7534(23)01932-4

Authors

Y. Mao1, X. Wu2, N. Xu3, Y. Bai4, D. Wang5, X. Chen6, X. Yin7, Y. Deng8, J. Yang9, J. Zhang10, J. Tang11, Y. Huang12, J. Li13, M. Xu14, N. Li15, Y. Mao16, A. Gozman17, J. Xu18

Author affiliations

  • 1 Gastroenterology, Renji Hospital Shanghai Jiaotong University School of Medicine, 200001 - Shanghai/CN
  • 2 Gynecologic Oncology, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN
  • 3 Medical Oncology Department, The First Affiliated Hospital of Medical School of Zhejiang University, 310009 - Hangzhou/CN
  • 4 Nangang, Harbin Medical University Cancer Hospital, 150081 - Harbin/CN
  • 5 Gynecologic Oncology, Chongqing University Cancer Hospital, 400030 - Chongqing/CN
  • 6 Gynecologic Oncology, Obstetrics & Gynecology Hospital of Fudan University, 200090 - Shanghai/CN
  • 7 Gastroenterology And Urology, Hunan Cancer Hospital, 410013 - Changsha/CN
  • 8 Clinical Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, 510655 - Guangzhou/CN
  • 9 Clinical Oncology, Fujian Provincial Cancer Hospital, 350014 - Fuzhou/CN
  • 10 Gynecologic Oncology, Affiliated Cancer Hospital of Guangxi Medical University, 530021 - Nanning/CN
  • 11 Gynecologic Oncology, Hunan Cancer Hospital, 410000 - Changsha/CN
  • 12 Gynaecologic Oncology, Hubei Cancer Hospital, 430035 - Wuhan/CN
  • 13 Medical Oncology, The First Affiliated Hospital of Xiamen University, 361003 - Xiamen/CN
  • 14 Clinical Research, MSD (China) Co., Ltd., 100012 - Beijing/CN
  • 15 Statistics, MSD (China) Co., Ltd., 100012 - Beijing/CN
  • 16 Clinical Research, MSD (China) Co., Ltd., 100012 - Shanghai/CN
  • 17 Clinical Research - Oncology, Merck & Co., Inc., 07065-0900 - Rahway/US
  • 18 Gastrointestinal Oncology, The Fifth Medical Center of Chinese People's Liberation Army General Hospital, 100039 - Beijing/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 136P

Background

The multicohort KEYNOTE-158 (NCT02628067) trial supported the US FDA and EMA approval of pembrolizumab across multiple microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors. The incidence of MSI-H/dMMR advanced cancer in patients (pts) of Chinese descent is similar to that reported in Western populations (Liu et al 2019, Cancer Research 79:616). In cohort L of KEYNOTE-158, we evaluated the efficacy and safety of pembrolizumab in pts of Chinese descent with MSI-H/dMMR solid tumors.

Methods

In this nonrandomized, phase 2, open-label trial, pts aged ≥ 18 years of Chinese descent were enrolled. These pts had to have confirmed MSI-H/dMMR unresectable or metastatic cancers who had ≥1 prior lines of therapy. Eligible pts received 200 mg pembrolizumab Q3W for up to 35 cycles, until progression, unacceptable toxicity, or pt/investigator withdrawal. MSI-H/dMMR status was assessed centrally by PCR or ICH. The primary endpoint was ORR per RECIST 1.1 by independent central review. Secondary endpoints were DOR, PFS, OS and safety. The database cut-off date was July 26, 2022.

Results

At data cut-off, a total of 24 pts were enrolled of which 20 pts were for efficacy evaluation having at least 6 months (mo) of follow-up. The overall ORR was 70.0% (95% CI: 45.7%- 88.1%) for the 20 pts. The median DOR was not reached (NR) (range, 2.1+ - 19.3+) with a 12-mo DOR rate of 85.7%. Median PFS was NR (95% CI: 15.8-NR) with an 18-mo PFS rate of 68.0%. The median OS was NR (95% CI: 9.5, NR) with an 18-mo OS rate of 80.2%. Treatment-related adverse events (AE) were reported in 19 (79%) of the 24 pts enrolled. Grade ≥3 treatment-related AEs occurred in 4 (17%) pts with no grade 5 AEs. Immune-mediated AEs occurred in 8 pts (33%). Of these pts, 2 (8%) had grade 3 AEs (myositis or rash in 1 pt each). No grade 4 or 5 immune-mediated AEs occurred.

Conclusions

Pembrolizumab provided clinically meaningful antitumor activity and durable responses in pts of Chinese descent with MSI-H/dMMR tumors, with a manageable safety profile. No new safety signals were identified. These results are consistent with those reported for patients in the global population.

Clinical trial identification

NCT02628067; first posted on December 11, 2015.

Editorial acknowledgement

Editorial assistance provided by Jose Casasnovas Nieves, PhD, an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Legal entity responsible for the study

Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Funding

Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Disclosure

Y. Huang: Financial Interests, Institutional, Funding: MSD. M. Xu, N. Li: Financial Interests, Personal, Full or part-time Employment: MSD China. Y. Mao: Financial Interests, Personal, Full or part-time Employment: MSD China; Financial Interests, Personal, Stocks/Shares: Merck & Co., Inc., Rahway, NJ USA. A. Gozman: Financial Interests, Personal, Full or part-time Employment: Merck Sharp & Dohme Corp.; Financial Interests, Personal, Stocks/Shares: Merck & Co., Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.